Phase-3 trial of Bharat Biotech's Covaxin commences in AIIMS

Phase-3 trial of Bharat Biotech's Covaxin commences in AIIMS

Deccan Herald
PTI,

The phase-three human clinical trial of indigenously developed anti-coronavirus vaccine candidate Covaxin began at the AIIMS here on Thursday with Dr M V Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose.

'Covaxin' is being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Dr Srivastava was the first one to receive the shot, which would be given to around 15,000 volunteers at the AIIMS over the next few days, sources said.

The first dose of 0.5 ml intramuscular injection was given to four volunteers. They were under observation for two hours and will be monitored for the next few days, a source said.

Disclaimer: This is an automatically aggregated article/story by a computer program and has not been created or edited by Newsdig.in.

World COVID19 Meter

115323235

Cases

90996584

Recovered

2560713

Deaths
Last updated: GMT
Advt
Advt
Advt
sitemap Disclaimer
Newsdig.in 2019